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Abstract  
Background: Prebiotics and probiotics (synbiotics) can modify gut microbiota and have 
potential in allergy management when combined with amino acid-based formula (AAF) for 
infants with cow‟s milk allergy (CMA). 
Methods: This multicenter, double-blind, randomized controlled trial investigated the effects 
of an AAF including synbiotic blend on percentages of bifidobacteria and Eubacterium 
rectale/Clostridium coccoides group (ER/CC) in feces from infants with suspected non-IgE-
mediated CMA. Feces from age matched healthy breastfed infants were used as reference  
(HBR) for primary outcomes. CMA subjects were randomized and received test or control 
formula for 8 weeks. Test formula was a hypoallergenic, nutritionally complete AAF 
including a prebiotic blend of fructo-oligosaccharides and the probiotic strain 
Bifidobacterium breve M-16V. Control formula was AAF without synbiotics. 
Results: Thirty-five (test) and 36 (control) subjects were randomized; HBR included 51 
infants. At week 8, median percentage of bifidobacteria was higher in test group vs control 
group (35.4% vs 9.7%, respectively p<0.001), whereas ER/CC was lower (9.5% vs 24.2%, 
respectively; p<0.001). HBR levels of bifidobacteria and ER/CC were 55% and 6.5%, 
respectively.   
Conclusion: AAF including specific synbiotics, which results in levels of bifidobacteria and 
ER/CC approximating levels in HBR group, improves the fecal microbiota of infants with 
suspected non-IgE-mediated CMA. 
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Introduction 
Cow‟s milk allergy (CMA) affects up to 5% of infants and children in Western countries [1-
3], although the number of challenge-proven cases may be lower [4]. CMA is associated with 
a range of distressing and potentially severe clinical symptoms affecting the skin, 
gastrointestinal (GI) tract and less commonly, the respiratory tract [5]. Infants with non-IgE 
CMA generally have delayed symptoms [6] and present particular challenges because of 
difficulty in diagnosis, lack of validated tests, and a paucity of clinical studies [7]. When 
exclusive breast feeding is not possible, or there is failure of control of symptoms when dairy 
(+/- soya) is eliminated out of the maternal diet, dietary management guidelines for infants 
with CMA recommend extensively hydrolyzed formula (eHF) for mild cases and amino acid-
based formula (AAF) for severe cases. When eHF is not tolerated and fails to resolve allergy 
symptoms AAF is recommended [6, 8].  
Aberrant composition and diversity of gut microbiota in early life may disrupt development 
of the immune system [9-11], which is associated with allergy-related diseases [12-14], 
including food allergies, such as CMA [15]. A study of infants with CMA showed that gut 
microbiota composition at 3 to 6 months was associated with allergy resolution by the age of 
8 years [16], suggesting that during infancy gut microbiota could be a potential mechanism to 
influence food allergy outcomes in childhood. 
Studies showing that prebiotics and probiotics, or their combination (synbiotics), can 
positively modulate the composition of gut microbiota [17-21] provided the rationale to 
investigate such an approach in CMA. In addition, clinical studies of eHF supplemented with 
probiotics showed improved symptoms in infants with CMA [22-25]; however, eHF may not 
be the most appropriate formula for patients with non-IgE CMA, such as those presenting 
with faltering growth or those with persistent clinical symptoms when using eHF  [6] and an 
AAF is recommended in such cases [8]. Clinical studies in healthy infants [26] and infants 
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with CMA [26, 27] showed that synbiotic-supplemented AAF was hypoallergenic, well 
tolerated, and supported normal growth [26, 27]. Based on these findings, we conducted a 
randomized trial to assess the effect of an AAF with a specific and optimized synbiotic blend 
on fecal microbiota composition and to explore clinical effectiveness in infants with 
suspected gastrointestinal non-IgE mediated CMA [28]. This is the first randomized trial of a 
synbiotic-supplemented AAF exclusively in infants with suspected non-IgE CMA and 
includes an age-matched healthy breastfed reference group (HBR).  
  
©    2017 Macmillan Publishers Limited. All rights reserved.
 6 
 
Methods 
Trial design 
This was a multicenter, double-blind, randomized controlled trial including subjects with 
suspected non-IgE CMA and a non-randomized reference group (HBR). Subjects were 
recruited by Great North Children‟s hospital, Newcastle; Barts/Royal Hospital, Guys & St. 
Thomas‟ Hospital, GOSH, London; Royal Alexandra Childrens Hospital, Brighton in the 
UK.  In addition by University Hospital Padova, Padua; University Hospital Verona, Verona 
in Italy and CU St. Luc, University Hospital; Huderf, Brussels in Belgium, and Umeå 
University, Umeå in Sweden. Eligible subjects, enrolled from first October 2013 till 30 April 
2015, were stratified based on predominant, investigator-assessed symptoms (skin or GI) and 
randomly allocated to either test or control formula. The random allocation, by using a central 
Interactive Web Response System (Orca Pharma); was perfomed by a generated 
sequence/algorithm using block randomization to ensure that test and control formulas were 
assigned equally. Formulas were identically packaged in 400g tins and labeled with a one-
letter code so that parents/guardians and those assessing outcomes were blind to the group 
assignment. 
Test and control formulas were given for 8 weeks, after which subjects switched to a 
prescribed formula appropriate for their condition and age according to local clinicians choice 
and practice. Cow‟s milk protein was introduced depending on local clinical practice. 
Subjects continued test or control formula if an AAF was considered the most appropriate 
approach for dietary management of clinical symptoms. Solids introduced in diets of the 
subjects were recorded by means of food diaries. The trial duration from screening to 
completion was a maximum of 28 weeks.  
The trial was approved by the ethics committees of participating centers and all 
parents/guardians provided written informed consent. 
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Participants 
Subjects were randomized if they were aged <13 months and had a clinical history or strong 
suspicion of an allergic reaction to cow‟s milk protein, based on a robust diagnostic work-up 
(Table 1) collectively designed by a multidisciplinary team of clinicians, comprising pediatric 
gastroenterology, allergy, and immunology specialists. The defined inclusion criteria (Table 
1) included a negative specific IgE test (ImmunoCAP), and/or a negative skin prick test with 
cow‟s milk protein, if a test was performed (testing was not mandatory per protocol). In 
addition at study entry the subjects had at least one of the following (GI) symptoms related to 
inclusion of cow‟s milk protein in their diet: faltering growth; frequent regurgitation or 
vomiting; extended periods of diarrhea with a negative stool examination (negative 
microbiology and virology laboratory tests); soft stool constipation; blood in stool; iron-
deficiency anemia due to occult or macroscopic blood loss in stools not due to infection or 
dietary insufficiency; endoscopically confirmed eosinophilic enteropathy; or persistent 
distress or colic (> 3 hours per day at least 3 days per week over 3-week period). Infants were 
excluded for the following reasons: birth weight <2500 g, <37 weeks gestation requiring 
specific premature infant formula at study entry, severe concurrent illness, functional GI 
symptoms without suspicion of atopy and food allergy, immune, autoimmune or gluten 
sensitive enteropathy, food protein-induced enterocolitis syndrome, acute or chronic diarrhea 
secondary to a confirmed infectious gastroenteritis, behavioral disorders with food aversion 
or food phobia, GI surgery, syndromes commonly associated with functional GI disorders, 
and the use of probiotics, systemic antibiotics or anti-mycotic drugs 4 weeks preceding study 
entry. 
Two weeks after randomization symptom resolution was evaluated and subjects with 
persistent symptoms were reassessed by the investigator and only subjects with suspicion of, 
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or confirmed, non-IgE CMA continued in the study. Subjects not eligible at reassessment 
were withdrawn (Figure 1).  
The non-randomized, HBR group comprised infants who were exclusively breastfed until 7 
months of age. Healthy subjects of 7 months or older did consume solids, which were 
recorded in dietary diaries. In addition the subjects did not have any concurrent illness or 
clinical history of allergy, did not receive any treatment or nutritional intervention, and were 
within a similar age range to subjects in the randomized groups. Infants in the HBR group 
were prospectively recruited from selected study centers and local community centers.  
Interventions in the randomized arms 
The test formula was a hypoallergenic, nutritionally complete AAF (Neocate LCP; Nutricia 
Advanced Medical Nutrition, Liverpool, UK) containing a prebiotic blend of chicory-derived 
neutral oligofructose and long-chain inulin (BENEO-Orafti SA, Oreye, Belgium) (9:1 ratio at 
a total concentration of 0.63g/100ml) and a probiotic strain Bifidobacterium breve M-16V 
(Morinaga Milk Industry, Tokyo, Japan) at a concentration of 1.47 x 10
9
 colony-forming 
units (CFU)/100 mL formula. The control formula was a commercially available AAF 
without synbiotics (Neocate LCP; Nutricia Advanced Medical Nutrition, Liverpool, UK). 
Subjects were instructed to consume a minimum, age-specific, daily formula intake from the 
end of week 2 (infants aged 0 to 6 months, 500ml; 6–8 months, 450ml; >9 months, 350ml). 
Assessments 
Medical history was documented by the clinician, for both test and control group, at baseline 
(week 0) and via 24-hour recall of baseline presenting complaints. Stool samples for analysis 
were collected by parents/guardians at week 0, if possible under the supervision of a 
healthcare professional, and then at home at weeks 8, 12, and 26. Samples collected into 10 
mL stool containers (Greiner Bio-One, Kremsmünster, Austria) were immediately frozen at 
©    2017 Macmillan Publishers Limited. All rights reserved.
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−80° C in the clinic or at −20° C in a home freezer before transfer to the clinic storage 
facility. Parents/guardians completed a diary to record stool characteristics (frequency, color, 
and consistency; over 3 days during weeks 1, 4, 8, 12, and 26), study formula intake (volume 
consumed over 7 days during weeks 1, 4, and 8), and diet evaluation (type of foods eaten by 
the subject at the end of each week during weeks 1, 4, 8, 12, and 26). Skin symptoms (atopic 
dermatitis), respiratory symptoms (blocked nose, sneezing, coughing, and wheezing), GI 
symptoms (vomiting, spitting up, and gas/wind), and general symptoms (sleep pattern last 
night, ease to settle or burp after feeds, visual signs of discomfort e.g. back arching and 
crying due to irritability) were recorded in the diary (collected over 3 days during weeks 1, 4, 
8, 12, and 26) and reviewed by the investigator during clinic visits. In order to collect HBR 
stool samples that could be age matched with the week 8 age range of the CMA infants, stool 
samples from HBR were collected at one timepoint, or more if feasible for infant and parents. 
The stool sample collection was as described above and accompanied with a completed diet 
diary and stool characteristics assessment. After study completion, and prior to deblinding of 
the groups, age matching HBR samples were selected for reference analyses.  
Objectives and outcomes 
The primary objective was to assess the effect of test formula on fecal percentages of 
bifidobacteria and Eubacterium rectale/Clostridium coccoides group (ER/CC) at 8 weeks, 
determined by FISH analysis using 16S rRNA-targeted oligonucleotide probes, as described 
previously [29]. Bifidobacteria are typically abundant in healthy breastfed infants [30] and 
show stable and increased levels in early childhood compared with adults [31]. Since 
maturation to adult-like profiles may extend beyond 5 years of age, ER/CC was selected as a 
marker because it typically is one of the first adult-like bacterial groups appearing in the 
infant gut [30, 31]. 
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Assessing the effects of test formula on stool characteristics at weeks 0 and 8 was a 
secondary objective. 
Measuring clinical effectiveness of test formula on allergic symptoms was an exploratory 
objective. Skin symptoms at weeks 0 and 8 were evaluated by the SCORing Atopic 
Dermatitis (SCORAD) rating scale [32]. Parent-reported rating scales for skin, respiratory, 
GI, and general symptoms were collected using a four-point scale where a score of (1) was 
taken as normal with no symptoms. Assessed parent reported symptoms were evaluated 
together with the clinician during visits. 
The frequency and severity of adverse events and use of concomitant medication were used 
to assess safety and tolerability. Standard anthropometric measurements were recorded to 
assess growth. 
Statistics 
Sample size estimation was based on effect size difference of 26.4% in bifidobacteria and 
23.6% in ER/CC group [29]. Assuming a significance level of 5% using a two-sided 
statistical test and Hochberg principle for two parameters, a sample size of 20 completers per 
study arm gave 80% power to observe an effect. Assuming estimated drop-out rates of up to 
25% of subjects whose symptoms did not resolve within 2 weeks of starting AAF and 20% 
for other reasons, 68 subjects were to be recruited. Following a semi-blinded interim analysis 
by an independent committee it was decided to keep the sample size unchanged. This 
committee consisted of a clinical studies expert, a gut microbiology expert and a statistician. 
These experts were not involved in any discussion or decision regarding conduct of the study 
or study results after they evaluated semi-blinded data. 
Overall statistical analyses were performed comparing test with control group. To bring 
microbiota outcomes in a context of a healthy situation, levels of a reference group were 
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determined and used as reference only and not as a treatment group. Two primary outcome 
parameters (bifidobacteria and ER/CC) were recorded as percentages of total fecal bacteria. 
All analyses were performed on intention-to-treat dataset (ITT), defined as all randomized 
subjects. Analysis of covariance (ANCOVA) was performed with a between-subjects factor 
“group” (test vs. control) and both the stratification factor (skin or GI) and the baseline 
measure as covariate (the primary model). The model-based intervention effect size was 
calculated and the significance of the fixed parameter „group‟ estimate was evaluated. To 
evaluate potential influence on primary outcome, additional sensitivity analyses were 
performed for the predetermined covariates: age at baseline, mode of delivery, sex, antibiotic 
use during study, introduction of weaning foods, total duration of breastfeeding, intake of 
proton pump inhibitors (PPIs) or H2 antagonists, study site, and country. For sensitivity 
analysis 1 (including only age at baseline as covariate) the estimate was compared with the 
estimate of the primary model; for sensitivity analysis 2 (including age at baseline and one of 
the other covariates) the estimate was compared with the estimate of sensitivity analysis 1. 
Secondary and exploratory outcome parameters were reported descriptively. P-values for 
SCORAD (change from baseline), clinical symptoms and stool frequency (levels at week 8) 
were based on Van Elteren test comparing test and control accounting for the stratification 
factor (skin or GI symptoms). P- values for mean daily formula intake were tested by t-test 
and median daily intake by means of Wilcoxon sum rank test.  
Statistical analyses were performed by using SAS® (SAS Enterprise Guide version 4.3 or 
higher) for Windows (SAS Institute Inc., Cary, NC). Results are expressed as mean values ± 
SD unless stated otherwise. 
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Results 
A total of 71 subjects with suspected non-IgE CMA were recruited from 11 centers in the 
UK, Italy, Belgium, and Sweden. Figure 1 summarizes the flow of patients in the randomized 
treatment arms; 35 subjects were randomized to test formula and 36 to control formula. Early 
withdrawal related adverse events were constipation (n=1) and infantile colic (n=1) and 
related serious adverse event (n=1) was viral laryngitis. The events were reported as unlikely 
and not related to study formula.  
A total of 110 stool samples from 60 healthy subjects were collected and 51 subjects were 
considered eligible following predefined criteria; subsequently 51 stool samples from these 
subjects were selected as healthy reference samples by age-matching with age of CMA 
subjects at week 8 of intervention (Table 2). Characteristics of subjects in the randomized 
treatment arms were well balanced with respect to baseline demographics –except for mode 
of delivery which was twice as high in the control group compared to test group (Caesarean 
section 41.7% and 20.0%, respectively; Table 2). Most subjects were Caucasian and 60% 
were recruited in the UK, whereas Sweden contributed most infants in the HBR group. Most 
CMA subjects suffered from the following symptoms associated with cow‟s milk protein 
ingestion:  Frequent regurgitation or vomiting (72%), Persistent distress or colic (70%), 
eczema (52%), a change in behavior such as irritability or crying (44%), soft stool 
constipation (41%), and faltering growth (34%; Table 3). Gastrointestinal, skin, respiratory 
and other symptoms were well balanced at baseline. Gastrointestinal symptoms were the 
predominant complaint in 90.1% of the subjects, while the remainder suffered predominantly 
from skin symptoms. Most infants in test (29%, 46%) and control groups (36%, 53%) were 
already on hydrolysate formula or AAF, respectively, at study entry. The average amount of 
study formula intake during the study did not differ between study groups. In week 1 mean 
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daily intake (±SD) was 602 (±247) and 627 (±205) mL in test and control group, respectively 
(p=0.646). Mean daily intake for test and control was 629 (±213) and 660 (±238) mL 
(p=0.603) and 652 (±176) and 639 (±212) mL (p=0.797) in weeks 4 and 8, respectively. 
Nature and frequency of solid foods consumed during the study were well balanced between 
test and control groups as well between HBR group and both CMA groups at wk 8 (data not 
show).  
The primary outcome showed statistically significant differences (P<0.001) between test and 
control groups at week 8 in the fecal composition of bifidobacteria and ER/CC (Figure 2). In 
subjects given AAF with synbiotics, median percentages of bifidobacteria were higher at 
week 8 compared with those in the control group (35.4% vs 9.7%, respectively), whereas 
median percentages of adult-like ER/CC were lower (9.5% vs 24.2%, respectively). The 
differences between test and control arms were statistically significant for bifidobacteria 
(+20.937% [95% confidence intervals 10.14, 31.74]; P<0.001) and ER/CC (−14.115% 
[−22.21, −6.02]; P<0.001). At wk 8 median percentages of bifidobacteria and ER/CC of the 
test group were 35.4% and 9.5% respectively, which approximated the levels in the the HBR 
(55% and 6.5%) more so than the levels in the control group(9.7% and 24.2%). The 
sensitivity analyses considered intake of PPIs or H2 antagonists as potential confounder for 
bifidobacteria analyses and antibiotic use and sex as potential intervention effect modifiers. 
Including intake of PPIs or H2 antagonists as an additional covariate into the ANCOVA 
model, however, did not change the outcome of the primary parameters bifidobacteria 
(P<0.001) and ER/CC (P<0.001) at week 8. A subgroup analysis on subjects that did not take 
any systemic antibiotics (n=47) showed that differences between test and control were 
statistically significant for both bifidobacteria (P<0.001) and ER/CC (P<0.001; supplemental 
Figure S1). In addition, the differences between test and control at week 8 were also 
statistically significant in both males (n=41) and females (n=15) for bifidobacteria (P=0.037 
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and P<0.001, respectively) and ER/CC (P=0.047 and P=0.032, respectively; supplemental 
Figure S1). The sensitivity analyses showed that all other predetermined covariables - 
including age at baseline, mode of delivery, introduction of weaning foods, total duration of 
breastfeeding, study site, and country -did not significantly influence primary outcome.  
Stool frequency score was lower in the test group than the control group (1.88±0.19 vs. 
1.98±0.15; P=0.015); however, all other measures of stool characteristics were not 
statistically significantly different between groups at week 8 (data not shown).  
In exploratory analyses of clinical outcomes, no statistically significant differences were 
observed at week 8. Figure 3 shows clinical symptoms reported at weeks 0, 1, 4 and 8. GI 
symptoms were predominant in the study population. Reported scores for GI and general 
symptoms were, compared to other assessed outcomes, relatively high at baseline (2.0 to 2.5) 
and decreased over time (Figure 3). In contrast, reported scores for skin symptoms were 
relatively mild at baseline (generally below 1.5), and showed no statistically significant 
changes over 8 weeks. SCORAD decreased between weeks 0 and 8, from 12.83±18.84 to 
9.63±12.45 in the test group and from 14.43±19.74 to 7.06±10.01 in the control group.  
Overall, there were no differences in the number of subjects reporting adverse events between 
test and control groups during the first 8 weeks (Table 4). The total number of concomitant 
medications taken was lower in subjects given test formula (82) compared with control (111) 
formula, although the number of subjects was not statistically significant between arms. 
Further evaluation showed a significantly lower percentage of subject in the test group 
needed medication related to the subcategory designated „systemic anti-infectives‟ (subgroup 
according to the Anatomical Therapeutic Chemical coding system, which includes anti-
bacterials for systemic use and vaccines) compared with control (8.6% vs 34.4%, 
respectively; P=0.018). 
©    2017 Macmillan Publishers Limited. All rights reserved.
 15 
 
Growth parameters were within the expected ranges for age and median Z scores for both 
groups were within 1 SD of the mean (data not shown). 
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Discussion 
The primary objective of modifying gut microbiota using an AAF with a blend of prebiotic 
fructooligosaccharides and the probiotic strain B. breve M-16V for 8 weeks in subjects with 
suspected non-IgE CMA was achieved. Percentages of bifidobacteria were higher and adult-
like ER/CC lower among infants given the AAF with these specific synbiotics compared with 
those given the AAF without synbiotics. 
This study was primarily designed to investigate if the synbiotic ingredients can improve the 
gut microbiota in infants with non-IgE CMA to achieve a microbial composition close to that 
seen in healthy, breastfed infants. Previous studies showing the effects of breast milk on gut 
microbiota [33, 34] helped to guide the development of this AAF, which contains a specific 
blend of prebiotics and probiotics. B. breve is a bacterial species found in human milk and the 
gut of healthy infants [33, 35] and in preclinical models B. breve M-16V was identified as the 
most potent anti-allergic probiotic strain tested [36]. Another model of established food 
allergy showed potential immune modulatory benefits of dietary intervention with a synbiotic 
combination of short- and long-chain fructooligosaccharides and B. breve M-16V [21]. The 
current study showed that microbial composition of infants with suspected non-IgE CMA 
who received the test formula was closer to the profile of the HBR group than those receiving 
control formula. Based on previous studies, we hypothesized that modifying the gut 
microbiota with these specific synbiotics may improve clinical symptoms associated with 
dysbiosis and dysregulated immune reactions in infants with CMA [37, 38]. Overall, 
exploratory GI and general symptoms improved over time, but were not statistically 
significantly different between test and control at week 8. This trial was not primarily 
designed or powered to show differences in clinical outcomes between groups and it is 
important to note that the majority of subjects were already receiving a hydrolysed formula or 
AAF at study entry, which confounds interpretation of the exploratory data analysis. 
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This randomized trial has several limitations. The trial was designed to evaluate the effects of 
AAF with synbiotics exclusively in subjects with non-IgE CMA. There is no standard test for 
the precise diagnosis of non-IgE allergy, raising the possibility that subjects with other 
conditions, for example other (food) allergy presentations, could dilute the trial population. 
The possibility of erroneous entry into the trial was addressed by using a robust diagnostic 
work-up (Table 1) collectively designed by a multidisciplinary team of clinicians, comprising 
pediatric gastroenterology, allergy, and immunology, and was based on careful symptom 
assessment by the investigators, with specific IgE testing and skin-prick testing (if assessed) 
to exclude any IgE-mediated CMA. Additional research is warranted to define precise 
biomarkers for this allergic phenotype.  
Consistent with scientific methodology it is essential to ensure patients meet diagnostic 
criteria for eligibility and undergo a double-blind placebo-controlled challenge to confirm 
symptomatology to cow‟s milk protein. Furthermore, as seen in clinical practice, determining 
disease resolution requires re-introduction of the food by food challenge or introduction at 
home. In the present trial, it was not mandatory for study subjects to have a food challenge to 
confirm CMA diagnosis, although this would have been ideal for the interpretation of the 
clinical outcomes. However, overall, in the context of our understanding of the many 
influences on the gut microbiota, the investigators do not believe this specific limitation of 
the study would have a meaningful influence on the primary outcome.  
One of the factors associated with microbiota development is the mode of delivery (i.e. 
caesarean or vaginal delivery) of an infant. In our study, twice as much caesarean delivered 
infants were randomized to the control group compared with test group (42% and 20%, 
respectively) and could therefore potentially influence the primary outcome. Our statistical 
analyses showed however that this factor did not influence current study outcome.  
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Furthermore, there is no recognized standard profile for the composition of a healthy 
microbiota during the dietary diversification period in early life. The trial design partly 
addresses this issue by using a HBR group to allow age-matched comparison of data; 
however, it is important to recognize that the reference population is not identical to the 
randomized groups, for example, with respect to predominant country of origin, mode of 
delivery (14% caesarean section born vs. 20 and 42% in test and control group, 
respectively),general health status, allergic symptoms, and dietary management. The authors 
feel that despite these limitations this HBR group is a good representation of a healthy 
microbiota to function as reference . The duration of formula administration and length of 
follow-up mean there is only limited scope for this trial to assess longer term changes in gut 
microbiota. 
This randomized controlled trial adds to the evidence base for prebiotics and probiotics in the 
alteration of infant microbiota and potentially the dietary management of CMA [22-25, 27, 
39-42]. However, caution is required in making comparisons between studies, which had 
different trial entry criteria and tested a range of dietary management strategies. The test 
formula in this trial was a hypoallergenic, nutritionally complete AAF with a specific 
composition of prebiotics and probiotics not derived from cow‟s milk ingredients. The 
formula composition was similar to the one tested by Harvey and colleagues [26], but 
excluded the pectin-derived acidic oligosaccharides. Data with this formula cannot be 
extrapolated to other types of formula, e.g. eHF, or formulas containing different types of 
prebiotics or alternative strains of probiotics.  
Safety concerns have been expressed with other infant formulas containing different 
probiotics [43, 44] and it is important that safety is established in clinical trials for each 
specific formula in an appropriate population [45]. The synbiotic-supplemented AAF in this 
trial was shown to be safe in terms of adverse events, use of concomitant medications, and 
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achievement of growth targets [26]. Several studies have shown that B. breve M-16V is safe 
in infants, including preterm neonates [26, 27, 46]. Although the addition of these specific 
synbiotics to AAF improves the composition of the gut microbiota so that it more closely 
resembles the composition observed in breastfed individuals, the results of this trial do not 
change the recommendation that infants with CMA should be fed with human breast milk if 
possible. 
While these results are specific to subjects with non-IgE mediated CMA, Burks et al [28] 
showed that an AAF, including ingredients from the current synbiotic blend, was safe in 
patients with IgE and non-IgE mediated CMA. An ongoing clinical study (Netherlands Trial 
Register NTR3725) includes infants with confirmed IgE-mediated CMA, randomly allocated 
to receive AAF with or without synbiotics for 12 months, and will assess cow‟s milk 
tolerance acquisition over 24 months. The ongoing and reported trial will inform future 
studies primarily focusing at clinical outcomes in the specific CMA populations. 
Based on data showing significant effects on the composition of gut microbiota that extend 
beyond an increase in bifidobacteria, we conclude that the AAF including the specific 
synbiotics of fructooligosaccharides and B. breve M-16V used in this trial was equally well 
tolerated as AAF without synbiotics, suitable for dietary management, and supports 
microbiota development of infants with suspected non-IgE mediated CMA. 
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Figure 1. CONSORT diagram showing the flow of subjects in the randomized arms. ITT = 
intent to treat.  Early withdrawal related adverse events were constipation (n=1) and infantile 
colic (n=1) and related serious adverse event (n=1) was viral laryngitis. The events were 
reported as unlikely and not related to study formula. 
Figure 2. Percentages of bifidobacteria (a) and adult-like ER/CC (b) at weeks 0 and 8 in 
subjects given test formula or control formula (ITT). The gray shaded area represents the 
sample 25
th
 to 75
th
 percentile of the healthy reference group (healthy, breastfed subjects) and 
the gray horizontal lines represent the minimum and maximum values of the healthy 
reference group. P values are based on ANCOVA comparing test vs. control with week 8 
values as outcome, stratification factor (skin or gastrointestinal symptoms) and imputed 
baseline values as covariate and intervention as fixed effect. 
Figure 3. Parent reported, clinician evaluated, symptoms at weeks 0, 1, 4 and 8 assessed 
on a 4-point rating scale specific for each symptom. Skin symptoms (redness, oozing, 
crusting, itchiness, dryness, and nappy rash) were rated as 1: none, 2: slight, 3: some, 4: a lot.  
Respiratory symptoms blocked nose and wheezing rated as 1: none, 2: mild, 3: moderate, 4: 
severe and coughing was rated as 1: none, 2: 1-2 times/day, 3: 3-5 times/day, 4: more than 5 
times/day. General and gastrointestinal symptoms vomiting was rated as 1: none, 2: 1-2 
times/day, 3: 3-4 days/day, 4: more than 4 times/day; spitting-up as 1: none, 2: after some 
feeds, 3: after all feeds, 4: between and after feeds; gas / wind as 1: none; 2: slight; 3: some; 
4: a lot; sleep pattern last night as 1: normal, 2: awake once, 3: awake 2-3 times, 4: awake 
more than 3 times; ease of settling or burping after feeds as 1: no problem at all, 2: slight 
difficulty, 3: some difficulty, 4: very difficult; visual signs of discomfort (e.g. back arching) 
as 1: none, 2: slight, 3: some, 4: a lot; and crying (due to irritability) as 1: none, 2: up to 1 
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hour, 3: 1-3 hours, 4: more than 3 hours. Data are shown as mean values +/- 95% confidence 
interval limits. 
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Table 1. Inclusion and exclusion criteria  
Inclusion criteria Exclusion criteria 
 Infants <13 months of age  Infants <2500g at birth 
 Clinical history or strong suspicion of an allergic 
reaction to cow’s milk protein with at least one of 
the following gastrointestinal symptoms: 
 Infants <37 weeks of gestation requiring 
premature formula at study entry 
a) Chronic poor weight gain after dietary inclusion 
of cow’s milk protein 
 Infants with severe concurrent illness 
b) Frequent regurgitation or vomiting whereby 
symptoms are related to the cow’s milk protein 
 Infants with functional gastrointestinal 
symptoms where atopy and food allergy is not 
suspected 
c) Extended periods of diarrhea with a negative 
stool examination (lab test negative)  
 Infants with (auto)immune and gluten sensitive 
enteropathy 
d) Soft stool constipation1 (with/without perianal 
rash not due to infection) 
 Infants with Food Protein-Induced Enterocolitis 
Syndrome (FPIES)
2
 
e) Blood in stool 
 Behavioral disorders with food aversion or food 
phobia 
f) Iron deficiency anemia due to occult or 
macroscopic blood loss in stool not due to 
infection 
 Infants who have acute of chronic diarrhea 
secondary to confirmed infectious 
gastroenteritis (lab test positive) 
g) Endoscopically confirmed eosinophilic 
enteropathy 
 Infants who have undergone gastrointestinal 
surgery (e.g. bowel resection, stoma) 
h) Persistent distress or colic (>3 hours/day, at 
least 3 days/week over 3 week period) 
 Infants with Down syndrome or other 
syndromes where functional gastrointestinal 
disorders are common 
 If performed results of specific IgE tests and/or 
SPT for cow’s milk protein are negative 
 Use of probiotic bacteria or probiotic 
containing drinks/supplements/formula 4 weeks 
prior to study 
 Expected minimum study formula intake per day at 
end of week 2, 500ml (0-6 months), 450ml (6-8 
months), 350ml (≥9 months) 
 Use of systemic antibiotics or antimycotics 4 
weeks prior to study 
1 
Soft stool constipation is a term used when a subject uses excessive straining to pass liquid or soft stool (with 
an occasional hard plug). 
2
 FPIES, which is associated with very severe symptoms, was excluded to reduce subject heterogeneity. 
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Table 2. Demographics of subjects with CMA and the healthy reference group. 
 
 
Test 
(N = 35) 
Control 
(N = 36) 
Total CMA 
(N = 71) 
 Healthy subjects 
(N = 51) 
Age at baseline (months)      
Mean (SD) 5.67 (3.24) 6.33 (2.71) 6.00 (2.98)  7.84 (3.25) 
Min - Max 1.8 - 12.8 1.2 - 11.6 1.2 - 12.8  2.6 - 14.2 
Sex (%)      
Female 28.6 25.0 26.8  45.1 
Male 71.4 75.0 73.2  54.9 
Race (%)      
Asian 5.7 2.8 4.2  0.0 
Black 2.9 0.0 1.4  0.0 
Caucasian / White 88.6 88.9 88.7  92.2 
Combination Of Above / Other 2.9 8.3 5.6  7.8 
Mode of delivery (%)      
Caesarean section 20.0 41.7 31.0  13.7 
Vaginal 80.0 58.3 69.0  86.3 
Country of residence (%)      
Belgium 17.1 13.9 15.5  0.0 
United Kingdom 60.0 69.4 64.8  29.4 
Italy 17.1 13.9 15.5  11.8 
Sweden 5.7 2.8 4.2  58.8 
N is number of subjects. Denominator for % is number of subjects in treatment group with non-missing data. 
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Table 3. Medical history of presenting complaints of subjects in the randomized arms at study baseline.  
 
Test 
(N=35) 
Control  
(N=36) 
Total  
(N=71) 
Medical history of presenting complaints as examined by clinician, N (%)    
Overall symptoms A change in behavior such as irritability or crying 12 (34.3%) 19 (52.8%) 31 (43.7%) 
Gastrointestinal symptoms Frequent regurgitation or vomiting related to cow’s milk protein 23 (65.7%) 29 (80.6%) 52 (72.3%) 
 Persistent distress or colic (>3 hrs/day ≥3 days/wk over a 3-wk period) 24 (68.6%) 25 (69.4%) 49 (69.0%) 
 Soft stool constipation (with/without perianal rash due to infection) 12 (34.3%) 17 (47.2%) 29 (40.8%) 
 Faltering growth after the dietary inclusion of cow’s milk protein 13 (37.1%) 11 (30.6%) 24 (33.8%) 
 Extended periods of diarrhea with a negative stool examination 8 (22.9%) 9 (25.0%) 17 (23.9%) 
 Blood in stool 10 (28.6%) 5 (13.9%) 15 (21.1%) 
 Endoscopically confirmed eosinophilic enteropathy 0 0 0 
Skin symptoms Eczema 16 (45.7%) 21 (58.3%) 37 (52.1%) 
 Urticaria 3 (8.6%) 4 (11.1%) 7 (9.9%) 
Respiratory symptoms Sneezing / nasal congestion 9 (25.7%) 12 (33.3%) 21 (29.6%) 
 Wheezing 5 (14.3%) 5 (13.9%) 10 (14.1%) 
 Conjunctivitis  1 (2.9%) 3 (8.3%) 4 (5.6%) 
 Dyspnea 1 (2.9%) 1 (2.8%) 2 (2.8%) 
 Stridor 1 (2.9%) 1 (2.8%) 2 (2.8%) 
 Dysphonia 0 0 0 
 Aphonia 0 0 0 
Other symptoms Hypotension for age 0 0 0 
Predominant complaint /  Skin symptoms 4 (11.4%) 3 (8.3%) 7 (9.9%) 
stratification factor Gastrointestinal symptoms 31 (88.6%) 33 (91.7%) 64 (90.1%) 
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Table 4. Adverse events and use of concomitant medications in test and control groups. 
 
Test 
(N=35) 
Control  
(N=36) 
P-value 
(Fisher’s 
exact test) 
Adverse events, N (%)    
Overall  Any adverse event 20 (57.1%) 23 (65.7%) 0.624 
Severity Mild 15 (42.9%) 15 (42.9%)  
 Moderate 4 (11.4%) 7 (20.0%)  
 Severe* 1 (2.9%) 1 (2.9%)  
Preferred term description
#
 Gastrointestinal disorders 11 (31.4%) 13 (37.1%) 0.802 
 Infections and infestations 10 (28.6%) 12 (34.3%) 0.797 
Concomitant medication, N (%)    
Overall Any concomitant medication 21 (60.0%) 28 (80.0%) 0.117 
Subcategory
§
 
Anti-infectives for systemic 
use 
3 (8.6%) 12 (34.4%) 0.018 
* Reported severe adverse events were feeding disorder of infancy or early childhood (test group) and 
bronchiolitis and feeding disorder of infancy or early childhood (control group). 
#
 The two most frequent reported preferred terms of adverse event are shown. 
§
 Only categories (of total 9 categories) with a statistically significant difference (P<0.05) are shown. 
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